Affimed (NASDAQ:AFMD) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Affimed (NASDAQ:AFMD) in a research report report published on Tuesday,Benzinga reports.

A number of other equities analysts also recently commented on AFMD. Stifel Nicolaus cut their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Friday, November 15th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Affimed in a report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Affimed Trading Down 5.1 %

NASDAQ AFMD opened at $3.00 on Tuesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. The firm has a 50 day simple moving average of $3.45 and a 200-day simple moving average of $4.48. Affimed has a one year low of $2.90 and a one year high of $8.95.

Affimed (NASDAQ:AFMD) last announced its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Affimed had a negative net margin of 7,836.26% and a negative return on equity of 193.84%. The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million. As a group, equities analysts forecast that Affimed will post -4.25 earnings per share for the current year.

Hedge Funds Weigh In On Affimed

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. lifted its position in shares of Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after buying an additional 15,108 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Affimed during the third quarter worth about $44,000. Intellectus Partners LLC increased its position in shares of Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 10,250 shares in the last quarter. Choreo LLC acquired a new stake in shares of Affimed in the 2nd quarter valued at about $54,000. Finally, FMR LLC grew its stake in Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares during the last quarter. 30.82% of the stock is owned by institutional investors and hedge funds.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.